AR033680A1 - Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales - Google Patents

Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales

Info

Publication number
AR033680A1
AR033680A1 ARP010104082A ARP010104082A AR033680A1 AR 033680 A1 AR033680 A1 AR 033680A1 AR P010104082 A ARP010104082 A AR P010104082A AR P010104082 A ARP010104082 A AR P010104082A AR 033680 A1 AR033680 A1 AR 033680A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
heteroaryl
heterocycloalkyl
aryl
Prior art date
Application number
ARP010104082A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Inc filed Critical Schering Corp
Publication of AR033680A1 publication Critical patent/AR033680A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP010104082A 2000-08-30 2001-08-27 Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales AR033680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22918300P 2000-08-30 2000-08-30

Publications (1)

Publication Number Publication Date
AR033680A1 true AR033680A1 (es) 2004-01-07

Family

ID=22860141

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104082A AR033680A1 (es) 2000-08-30 2001-08-27 Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales

Country Status (27)

Country Link
US (1) US20020198216A1 (OSRAM)
EP (1) EP1313725B1 (OSRAM)
JP (1) JP2004513885A (OSRAM)
KR (1) KR20030034161A (OSRAM)
CN (1) CN100384837C (OSRAM)
AR (1) AR033680A1 (OSRAM)
AT (1) ATE359281T1 (OSRAM)
AU (2) AU8845101A (OSRAM)
BR (1) BR0113675A (OSRAM)
CA (1) CA2420673A1 (OSRAM)
CO (1) CO5640109A2 (OSRAM)
DE (1) DE60127846T2 (OSRAM)
EC (1) ECSP034494A (OSRAM)
ES (1) ES2284686T3 (OSRAM)
HK (1) HK1054548B (OSRAM)
HU (1) HUP0302942A3 (OSRAM)
IL (1) IL154528A0 (OSRAM)
MX (1) MXPA03001849A (OSRAM)
NO (1) NO20030918L (OSRAM)
NZ (1) NZ524246A (OSRAM)
PE (1) PE20020486A1 (OSRAM)
PL (1) PL361103A1 (OSRAM)
RU (1) RU2293734C9 (OSRAM)
SK (1) SK2292003A3 (OSRAM)
TW (1) TWI268280B (OSRAM)
WO (1) WO2002018368A1 (OSRAM)
ZA (1) ZA200301545B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
CA2440555A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
EP1435959A2 (en) * 2001-10-09 2004-07-14 University of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
CA2520172C (en) * 2003-03-27 2012-10-02 Lankenau Institute For Medical Research Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor
WO2005000230A2 (en) * 2003-06-05 2005-01-06 Charles Achkar Methods of treating hyperproliferative cell disorders
WO2005001053A2 (en) * 2003-06-09 2005-01-06 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
ES2235611B2 (es) * 2003-07-25 2006-07-16 Universidade De Santiago De Compostela Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas.
ATE417041T1 (de) * 2003-08-07 2008-12-15 Schering Corp Neue farnesylproteintransferaseinhibitoren als antitumormittel
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
AU2005319182A1 (en) * 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
RU2361587C1 (ru) * 2008-02-14 2009-07-20 Михаил Владимирович Кутушов Лекарственное средство для лечения онкологических заболеваний
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
WO2020258211A1 (en) * 2019-06-28 2020-12-30 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
ZA914764B (en) * 1990-06-22 1992-03-25 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
ATE293622T1 (de) * 1998-12-18 2005-05-15 Schering Corp Farnesyl protein transferase inhibitoren

Also Published As

Publication number Publication date
PE20020486A1 (es) 2002-06-14
AU2001288451C1 (en) 2008-03-06
NO20030918L (no) 2003-04-29
EP1313725B1 (en) 2007-04-11
CO5640109A2 (es) 2006-05-31
HUP0302942A3 (en) 2007-02-28
HK1054548A1 (en) 2003-12-05
MXPA03001849A (es) 2003-06-04
JP2004513885A (ja) 2004-05-13
DE60127846T2 (de) 2008-03-06
DE60127846D1 (en) 2007-05-24
KR20030034161A (ko) 2003-05-01
EP1313725A1 (en) 2003-05-28
RU2293734C9 (ru) 2007-10-10
US20020198216A1 (en) 2002-12-26
AU2001288451B2 (en) 2007-05-24
SK2292003A3 (en) 2003-08-05
BR0113675A (pt) 2003-06-24
IL154528A0 (en) 2003-09-17
AU8845101A (en) 2002-03-13
PL361103A1 (en) 2004-09-20
CN100384837C (zh) 2008-04-30
NO20030918D0 (no) 2003-02-27
CN1471524A (zh) 2004-01-28
ATE359281T1 (de) 2007-05-15
TWI268280B (en) 2006-12-11
ES2284686T3 (es) 2007-11-16
ECSP034494A (es) 2003-04-25
CA2420673A1 (en) 2002-03-07
NZ524246A (en) 2004-11-26
HK1054548B (en) 2007-10-18
RU2293734C2 (ru) 2007-02-20
ZA200301545B (en) 2004-06-22
WO2002018368A1 (en) 2002-03-07
HUP0302942A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
AR063531A1 (es) Derivados de anilinopiperazina y composicion farmaceutica
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
AR064304A1 (es) Formulaciones de ansamicina y sus metodos de uso
AR070521A1 (es) Derivados de 4h-pirido[4,3-d]-pirimidin-4-ona,inhibidores de quinasas,composiciones farmaceuticas que los contienen,uso de los mismos para el tratamiento de enfermedades con proliferacion celular o autoinmunes y metodo de preparacion de intermediarios de sintesis .
AR067824A1 (es) Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer.
AR035548A1 (es) Compuestos organicos
AR092538A1 (es) Inhibidores de girasa triciclica
AR035333A1 (es) Glucopeptido sustituido, composicion farmaceutica que lo comprende, su uso en la fabricacion de medicamentos utiles para tratar enfermedades bacterianas y metodo para preparar dichos compuestos.
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR068106A1 (es) Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica
AR096461A1 (es) Anticuerpos conjugados de fármacos
PE20170775A1 (es) Derivados de benzodiazepina citotoxicos
JP2018516243A5 (OSRAM)
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR043190A1 (es) Derivados de quinoleina como inhibidores del factor inhibidor de la migracion de macrofagos y metodos para su identificacion. sintesis y composiciones farmaceuticas.
AR070460A1 (es) Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen
AR035371A1 (es) Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento
BR112014019478A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença.
AR078151A1 (es) Conjugados de acidos grasos y niacina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades metabolicas.
JP2018511628A5 (OSRAM)
AR085806A1 (es) Inhibidores triciclicos de girasa
AR039557A1 (es) Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales
AR064414A1 (es) Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano

Legal Events

Date Code Title Description
FB Suspension of granting procedure